Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-Current Deffered Revenue: 2013-2017

Historic Non-Current Deffered Revenue for Coherus Oncology (CHRS) over the last 2 years, with Mar 2017 value amounting to $725,000.

  • Coherus Oncology's Non-Current Deffered Revenue fell 97.80% to $725,000 in Q1 2017 from the same period last year, while for Mar 2017 it was $725,000, marking a year-over-year decrease of 97.80%. This contributed to the annual value of $669,000 for FY2016, which is 98.52% down from last year.
  • Latest data reveals that Coherus Oncology reported Non-Current Deffered Revenue of $725,000 as of Q1 2017, which was up 8.37% from $669,000 recorded in Q4 2016.
  • Coherus Oncology's Non-Current Deffered Revenue's 5-year high stood at $45.3 million during Q4 2015, with a 5-year trough of $595,000 in Q3 2016.
  • Its 3-year average for Non-Current Deffered Revenue is $23.7 million, with a median of $33.0 million in 2016.
  • As far as peak fluctuations go, Coherus Oncology's Non-Current Deffered Revenue soared by 39.67% in 2014, and later plummeted by 98.52% in 2016.
  • Over the past 5 years, Coherus Oncology's Non-Current Deffered Revenue (Quarterly) stood at $28.6 million in 2013, then surged by 39.67% to $39.9 million in 2014, then rose by 13.63% to $45.3 million in 2015, then slumped by 98.52% to $669,000 in 2016, then tumbled by 97.80% to $725,000 in 2017.
  • Its Non-Current Deffered Revenue was $725,000 in Q1 2017, compared to $669,000 in Q4 2016 and $595,000 in Q3 2016.